Guertin David A, Stevens Deanna M, Saitoh Maki, Kinkel Stephanie, Crosby Katherine, Sheen Joon-Ho, Mullholland David J, Magnuson Mark A, Wu Hong, Sabatini David M
Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
Cancer Cell. 2009 Feb 3;15(2):148-59. doi: 10.1016/j.ccr.2008.12.017.
mTOR complex 2 (mTORC2) contains the mammalian target of rapamycin (mTOR) kinase and the Rictor regulatory protein and phosphorylates Akt. Whether this function of mTORC2 is critical for cancer progression is unknown. Here, we show that transformed human prostate epithelial cells lacking PTEN require mTORC2 to form tumors when injected into nude mice. Furthermore, we find that Rictor is a haploinsufficient gene and that deleting one copy protects Pten heterozygous mice from prostate cancer. Finally, we show that the development of prostate cancer caused by Pten deletion specifically in prostate epithelium requires mTORC2, but that for normal prostate epithelial cells, mTORC2 activity is nonessential. The selective requirement for mTORC2 in tumor development suggests that mTORC2 inhibitors may be of substantial clinical utility.
雷帕霉素靶蛋白复合物2(mTORC2)包含哺乳动物雷帕霉素靶蛋白(mTOR)激酶和Rictor调节蛋白,并使Akt磷酸化。mTORC2的这一功能对癌症进展是否至关重要尚不清楚。在此,我们表明,缺乏PTEN的转化人前列腺上皮细胞在注射到裸鼠体内时需要mTORC2才能形成肿瘤。此外,我们发现Rictor是一个单倍剂量不足基因,删除一个拷贝可保护Pten杂合小鼠免受前列腺癌的侵害。最后,我们表明,仅在前列腺上皮中因Pten缺失导致的前列腺癌发展需要mTORC2,但对于正常前列腺上皮细胞,mTORC2活性并非必需。肿瘤发展对mTORC2的选择性需求表明,mTORC2抑制剂可能具有重要的临床应用价值。